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 Allografting is potentially curative for myeloma (MM) 1. Molecular remissions (MR) were 29 
reported after myeloablative and reduced-intensity conditionings 2,3. Before the “new drugs” era, a 30 
tandem approach with an autograft after high-dose melphalan (200 mg/m2) followed by a non-31 
myeloablative 200 cGy total body irradiation (TBI)-based allograft was designed in Seattle4. At a 32 
median follow up of 12.1 years, we report long-term clinical outcomes of minimal residual disease 33 
(MRD) kinetics by nested qualitative PCR and real-time quantitative PCR (qPCR) on a cohort of 34 
newly diagnosed patients treated with the Seattle approach. 35 
 Between December 1999 - July 2009, 26 patients (supplementary Table-S1) with suitable 36 
diagnostic bone marrow (BM) specimens for immunoglobulin heavy-chain gene rearrangement 37 
(IGH) sequencing were prospectively monitored for MRD. Patients were induced with 2-3 courses 38 
of vincristine-adriamycin-dexamethasone (VAD)-based regimens (20/26, 78%) (ClinicalTrial.gov, 39 
NCT-00702247), with 3 courses of bortezomib-thalidomide-dexametasone (VTD) 40 
(EudraCTNumber:2007-003707-12) (2/26, 8%) or with 4 courses of lenalidomide-dexamethasone 41 
(LD) (4/26, 14%) (ClinicalTrial.gov, NCT01264315) followed by the tandem transplant approach 4. 42 
No pre-emptive donor lymphocyte infusions or maintenance/consolidation treatment were allowed 43 
except for the 4 patients enrolled in protocol NCT01264315 who started LD maintenance.  44 
 The centralized MRD laboratory staff were blinded to clinical findings. BM samples were 45 
collected at diagnosis, after the autograft, at 1, 3, 6 months after the allograft and then every 6 46 
months or as clinically indicated. Patient-specific IGH rearrangements were amplified and direct 47 
sequenced using consensus sense primers derived from the framework region (FR) FR1 or FR2 and 48 
a consensus anti-sense primer derived from FR4, as previously published 5-8. Qualitative nested-49 
PCR for the IGH rearrangement was performed on genomic DNA as previously described and its 50 
sensitivity was 3.3x10-6 5-8. qPCR analysis was performed in all nested-PCR positive cases, when 51 
DNA leftovers were available, according to the Euro-MRD criteria 6. Molecular remission (MR) 52 
was defined as 2 consecutive negative MRD results by nested-PCR or, if nested-PCR was positive, 53 
as 2 consecutive negative MRD results by qPCR with minimal sensitivity of 5x10-5 (supplementary 54 
data). Overall, a molecular marker was found in 19/26 patients (73%) and 151 nested-PCR 55 
determinations on BM samples were performed (median per patient: 8; range, 4-12). 56 
 At the time of the allograft, 8/26 (31%) and 4/26 (15%) were in clinical complete remission 57 
(CR) and partial remission (PR) respectively (supplementary data). Twelve additional patients 58 
(46%) achieved CR and 1 patient PR after the allograft (overall response 96%). At a median follow-59 
up of 12.1 (6.52-15.2) years from diagnosis and 11.1 (5.5-14.2) years from the allograft, median 60 
overall survival (OS) was not reached and event-free survival (EFS) was 4 years. Cumulative 61 
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incidence of relapse was 3.8% at 1, 30.8% at 2 and 34.6% at 5 years. Interestingly, 5/26 (19%) 62 
patients relapsed with extra-medullary disease. Cumulative incidence of grade II-IV GVHD and 63 
chronic GVHD were 26.9% and 65.4%. MRD studies showed that, after the autograft, 3/19 patients 64 
(16%) were nested-PCR negative. After the allograft, the rate of PCR negativity remained low at 65 
month 1 and 3 (5/19, 26% and 3/19, 16%, respectively); then increased up to 44% (8/18) at month 6 66 
and 47% (7/15) at one year post-transplant (Table 1). Among the 7 patients with persistent nested-67 
PCR negativity, only one clinical relapse was observed (10 months after the last MRD 68 
determination), while 7/12 patients who did not reach MR relapsed (Figure 1). By qPCR analysis, 69 
overall tumor shrinkage throughout treatment resulted in 13.80 ln and always remarkable was tumor 70 
reduction after the autograft, the allograft and post-transplant graft-vs-myeloma (p<0.001) (Table 71 
1). A median tumor burden reduction of 4.59 ln was seen after the autograft and a further decrease 72 
of 4.83 ln 1 month after the allograft. At 3 months, MRD levels were similar to those observed right 73 
after the allograft  (+0.22 ln), whereas a further tumor reduction of 4.61 ln was observed at six 74 
months post-transplant. This finding was stable over time suggesting ongoing graft-vs-myeloma. At 75 
most time-points, patients in continuous CR showed a lower median tumor burden as compared 76 
with those who relapsed (p<0.001).  77 
 An important prognostic role of MR was observed. Overall MR occurred in 12/19 patients 78 
(63%). All patients in MR were also in CR. Median time to MR was 6 months (range: 1-18 months) 79 
and MR had a median duration of 27 months (range: 3-102 months) with 7 patients in continuous 80 
MR and clinical CR. Patients who achieved MR showed a significantly lower incidence of relapse 81 
(27.1% vs 71.4% at median follow-up, p=0.016) and better median EFS and OS (not reached vs 82 
17.5 months, p=0.010; not reached vs 40 months, p=0.027, respectively) as compared with those 83 
who did not achieve MR (Figure 1, supplementary Figure S1).  84 
 Our study shows that our tandem approach induced high rates of prolonged MR by both 85 
qPCR and nested-PCR (63% and 47% respectively). After a remarkable median follow up of 12 86 
years (range 6.5-15) from diagnosis, the achievement of MR by nested-PCR was significantly 87 
associated with better long-term OS and EFS, median durations of which had not yet been reached 88 
(Figure 1). Whether long-term persistence of MRD negativity coincides with disease eradication 89 
remains a matter of debate though MR of several years may cautiously suggest cure. With “new 90 
drugs” survival has dramatically improved especially in good prognosis patients 9. However, the 91 
vast majority of our patients (78%) were treated on protocols which predated the “new drugs” era 92 
and never received them either as induction or maintenance. Lenalidomide did not affect the 93 
achievement of MR in the 2 only patients with a molecular marker who received post-transplant 94 
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maintenance on protocol NCT01264315. One did not achieve MR and progressed 3 months after 95 
the start of lenalidomide and the other reached MR before starting it and died of multi-organ failure 96 
2 months later. These findings are consistent with persistent graft-vs-myeloma, potentially curative 97 
in a subset of patients. Moreover, there was no correlation between MRD status and chronic 98 
GVHD. Most patients had completely withdrawn the immuno-suppression that allowed high quality 99 
of life. At the time of this report, only 2 patients had remained on low dose steroids to treat limited 100 
chronic GVHD. Overall, NRM was 15% at 5 years. This underlines that, as for all other treatments, 101 
the lack of long-term disease control remains the principal cause of treatment failure after an 102 
allograft.  103 
Importantly, our group also recently reported long-term outcomes of the GIMEMA-VEL-104 
03-096 trial 10. A cohort of 39 patients treated with bortezomib-thalidomide-dexamethasone (VTD) 105 
after an autograft were monitored for MRD with both nested-PCR and qPCR as in the present 106 
study. At a median follow-up of 8 years, OS was 72% for patients in MR response versus 48% for 107 
those with MRD persistence (p=0.041). Moreover, 26 (67%) patients who achieved MR showed 108 
good disease control with median time-to-next therapy (TNT) of 42 months whereas TNT in 109 
patients with MRD reappearance and MRD persistence were 9 and 10 months respectively 110 
(p=0.706). Importantly, both studies were carried out in the same facility by the same laboratory 111 
staff who were blinded to clinical data.       112 
Thought results were controversial, most prospective comparative studies on autografting 113 
versus allografting were conducted before the era of new drugs 11-14. The annual reports of the  114 
EBMT activities have however shown a steady increase of the use of allografting in plasma cell 115 
dyscrasias. The role of the combination of “new drugs” with graft-vs-myeloma has not yet been 116 
explored in well designed prospective studies 1. Interestingly, one comparative study showed higher 117 
response rates to salvage therapies in the allograft patients and significantly longer OS from relapse 118 
after the allograft than after a second autograft 12. These findings support a strong synergy between 119 
donor T cells and new drugs.  120 
In one Phase II clinical trial the feasibility of bortezomib within a reduced-intensity 121 
conditioning and given as maintenance was evaluated 15. Sixteen high-risk patients relapsed after an 122 
autograft were enrolled. Nine/16 (56%) and 5/16 (31%) achieved CR and partial remission 123 
respectively. Three-year cumulative incidence of NRM, relapse and OS were 25%, 54% and 41% 124 
respectively. For the first time, this trial showed safety and efficacy of an intensified conditioning 125 
with a “new drug” in poor prognosis patients. The concept of maintenance treatment after an 126 
allograft was also introduced. These findings led to the design of a prospective multi-center trial 127 
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through the European Myeloma Network. The trial aims at optimizing clinical outcomes by 128 
reducing the risk of relapse and the incidence of GVHD with the integration of bortezomib and 129 
lenalidomide in the treatment schema. Candidates are high-risk myeloma patients, younger than 70 130 
years, with early relapse after first-line treatment with new drugs and autografting. Preliminary data 131 
will be available shortly (Perez-Simon, personal communication).  132 
Graft-vs-myeloma after non-myeloablative allografting determined prolonged rates of MR 133 
similar to those described after myeloablative allografting and higher than those recently reported 134 
after a planned treatment combination of an autograft with VTD consolidation 10. In the light of our 135 
and of others’ results, it may become ethical to evaluate in newly designed clinical trials the 136 
combination of graft-vs-myeloma with novel agents in young high-risk and/or early relapsed 137 
patients where life expectancy is poor also in the era of new drugs.   138 
 139 
Supplementary information is available at Leukemia’s website  140 
 141 
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Table 1. Molecular evaluation of MRD. Rates of nested-PCR negativity at each time-point   229 
(Table2-A) and tumour burden shrinkage, reported as observed marginal medians of ln qPCR 230 
results (Table2-B).  231 
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Figure 1. Long-term clinical outcomes after tandem auto-allo transplantation and according 259 
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to molecular remission status   260 
Probability of overall survival (A), event free survival (B) and relapse (C) of the study cohort (26 261 
patients) and of patients who reached molecular remission (MR) either by nested qualitative PCR or 262 
real-time quantitative PCR (qPCR) (no. 12) versus those who had persistent disease (no. 7). Median 263 
follow up was 12 years from diagnosis and 11 years after the allograft. 264 
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Table 1. Molecular evaluation of MRD. Rates of nested-PCR negativity at each time-point   (Table2-A) 
and tumour burden shrinkage, reported as observed marginal medians of ln qPCR results (Table2-B).  
 
Table 1-A 
 
Number of PCR 
negative patients 
 
 
Post 
autograft 
 
Post allograft 3 months FU 6 months FU 12 months FU 
Nested-PCR 16% (3/19) 26% (5/19) 16% (3/19) 44% (8/18) 47% (7/15) 
qPCR 16% (3/19) 37% (7/19) 37% (7/19) 44% (8/18) 53% (8/15) 
 
Table 1-B 
 
MRD burden 
(median value of ln 
qPCRresults) 
 
 
Post 
autograft 
 
Post 
allograft 
3 months FU 6 months FU 12 months FU 
Overall 6.91 2.08 2.30 -2.30 -2.30 
ContinuosClinical CR 5.64 1.10 1.10 -2.30 -2.30 
Relapsed 9.01 7.30 6.43 3.26 1.10 
 
Abbreviations: q-PCR, real time quantitative polymerase chain reaction; ln, natural logarithm; FU, follow-
up; MRD, minimal residual disease; CR,  complete remission. 
 
 
 FIGURE 1 
 
 
Figure 1. Long-term clinical outcomes after tandem auto-allo transplantation and according to 
molecular remission status   
Probability of overall survival (A), event free survival (B) and relapse (C) of the study cohort (26 patients) 
and of patients who reached molecular remission (MR) either by nested qualitative PCR or real-time 
quantitative PCR (qPCR) (no. 12) versus those who had persistent disease (no. 7). Median follow up was 12 
years from diagnosis and 11 years after the allograft. 
 
